Novo Nordisk study shows benefits of Tresiba in real-world setting

Novo Nordisk has announced the findings of a real-world study that offer further evidence of the positive outcomes its drug Tresiba can offer for diabetes patients.

A post-hoc analysis was carried out of data from the EU-TREAT study collected in a real-world clinical setting among people with type 1 and type 2 diabetes, demonstrating the benefits of switching to Tresiba from another basal insulin.

Switching to Tresiba reduced the rate of hypoglycaemia by 67 percent in people with controlled blood sugar levels, while for those whose blood sugar was too high, switching to Tresiba was also shown to significantly improve blood sugar levels.

It was also revealed that people with type 1 diabetes whose blood sugar levels were controlled experienced a 16 percent lower rate of hypoglycaemia when observed over six months, with blood sugar control maintained with a 13 percent lower dose of insulin.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer at Novo Nordisk, said: "This new analysis shows that people with diabetes who have switched to Tresiba in the real world benefit from this change, regardless of whether they did so to improve blood glucose control or reduce the risk of hypoglycaemia."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.